IND submission for THE-349 in EGFR-mutant NSCLC expected in Q4 2023
Development candidate nomination for BCR-ABL program in CML and Ph+ ALL expected in H1 2024
Read more at prnewswire.comAll information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
IND submission for THE-349 in EGFR-mutant NSCLC expected in Q4 2023
Development candidate nomination for BCR-ABL program in CML and Ph+ ALL expected in H1 2024
Read more at prnewswire.com| Symbol | Last | Chg | %Chg |
|---|---|---|---|
| THRX | 4.06 | unch | unch |
| Theseus Pharmaceuticals Inc | |||